Lilly’s Lepodisiran Slashes Heart Disease Risk Factor by 94% in Phase 2 Trial
Eli Lilly and Company announced groundbreaking Phase 2 results for its investigational siRNA therapy lepodisiran, which reduced lipoprotein(a) [Lp(a)] levels
Read moreEli Lilly and Company announced groundbreaking Phase 2 results for its investigational siRNA therapy lepodisiran, which reduced lipoprotein(a) [Lp(a)] levels
Read moreThe European Union has authorized AstraZeneca’s Forxiga (dapagliflozin) to expand the treatment for heart failure (HF) with reduced ejection fraction
Read moreDanish multinational pharmaceutical company Novo Nordisk and Japanese cardiac regenerative medicine specialist Heartseed have confirmed an exclusive global partnership and license
Read moreThe Janssen Pharmaceutical Companies of Johnson & Johnson revealed on Monday the submission of the supplemental New Drug Application (sNDA)
Read moreBristol Myers Squibb is strengthening its cardiovascular pipeline through a $13.1 Billion acquisition of biotech firm MyoKardia. The $13.1 Billion
Read more